CLX

Business Profile & Competitive Position

The Clorox Company operates in the Consumer Defensive sector within the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, with fiscal 2026 net sales of roughly $6.7 billion, about 9,200 employees, operations in approximately 25 countries, and sales in about 95 markets. Its consumer-facing portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional division sells under the Purell, CloroxPro, and Clorox Healthcare banners. In April 2026, Clorox completed the acquisition of GOJO Industries, expanding its health and hygiene footprint and strengthening its business-to-business presence.

The company’s reported net margin of 8.7% suggests a business with meaningful, though not dominant, pricing power. Household brands typically generate repeat purchases and shelf space, but an 8.7% margin also leaves limited cushion if input costs rise or promotional intensity increases. The far more striking figure is the ROE of -1,893.5%, which signals that shareholder equity is deeply impaired or that earnings are being measured against a very small or negative equity base rather than a healthy capital structure. In practical terms, this tells investors that the historical profitability alone does not translate into a strong return on book equity today. Any discussion of competitive moat must therefore be tempered: brand recognition is real, but the financial returns currently do not support a wide-moat narrative.

Financial Posture

Clorox currently carries a market capitalization of $9.9 billion and trades at a P/E ratio of 16.9. That multiple is not extreme for a consumer-staples name, yet it sits against the backdrop of a net margin of 8.7% and the same deeply negative ROE -1,893.5%. The disconnect between a mid-teens earnings multiple and a balance sheet that produces massively negative ROE is a reminder that P/E captures only one slice of the financial picture.

The stock’s low beta of 0.54 confirms its defensive classification: it historically moves less than half as much as the broader market. Still, the current snapshot shows the share price at $81.53, below the 50-day EMA of $91.26, with an RSI of 33.7 — near the threshold often viewed as short-term oversold. The gap between price and the 50-day EMA reflects sustained selling pressure rather than a quiet consolidation, which is consistent with the recent headlines flagging a new 52-week low.

Strategic Priorities & Outlook

Clorox’s most recent SEC 10-K filing lays out several near-term operational priorities. The company is executing its IGNITE strategy, built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Management also plans to complete and optimize a new enterprise resource planning (ERP) system and a broader digital transformation to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

On the operational front, Clorox intends to invest in strong brands, strategic digital capabilities, and a streamlined operating model to build a more resilient company that can deliver consistent, profitable growth. A major priority is the advance of health and hygiene expansion and portfolio optimization, including integrating the GOJO acquisition and growing professional and institutional markets.

These initiatives are not happening in a vacuum. Fiscal year 2026 saw declines in organic sales and earnings, with diluted EPS down 26%, partly due to macroeconomic headwinds and ERP transition timing that had pulled some sales into fiscal 2025. Customer concentration is another pressure point: Walmart accounted for 26% of consolidated FY2026 net sales, while the five largest customers represented about half of consolidated net sales. In addition, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, requiring Clorox to purchase P&G’s 20% interest; Glad retained core intellectual property licenses on a royalty-free basis.

Macro & Geopolitical Exposure

As a Household & Personal Products company, Clorox is exposed to several macroeconomic and geopolitical factors that are common across the industry. Consumer-staples demand is relatively stable, but volume growth and pricing power are sensitive to household budget pressure and the pace of private-label substitution. Input costs — including resins, chemicals, paperboard, and packaging — can swing with commodity markets and global supply-chain conditions. Freight, warehousing, and logistics costs also directly affect margins.

With sales in roughly 95 markets, foreign-exchange movements can create translation volatility. Regulatory risk is another standard feature of the industry, because cleaning, health, and personal-care products face scrutiny over ingredient safety, labeling, and environmental claims. Tariff and trade-policy changes can affect both imported inputs and export competitiveness. Finally, the concentrated retail customer base means that pricing negotiations with large distributors remain a persistent macro-style headwind for margin and working-capital flexibility.

Recent Developments

Recent headlines reinforce a cautious tone. On October 5, 2026, Benzinga published “Wall Street’s Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields,” which included Clorox among defensive names. On October 3, 2026, two Fool.com articles framed the stock’s challenges: one noted that Clorox, General Mills, and Constellation Brands were down between 22% and 33%, and another stated that “Clorox is Dealing With Several Years of Challenging Circumstances.” A day earlier, on October 2, 2026, DefenseWorld.net reported that “Clorox (NYSE:CLX) Reaches New 52-Week Low – Here’s Why.”

These stories, taken together, highlight the same pattern visible in the price action: a defensive, low-beta stock that has nonetheless sold off sharply and is setting fresh lows. The near-term narrative is less about recession risk and more about company-specific execution, margin pressure, and the ongoing integration of GOJO against a backdrop of weaker FY2026 results.

Earnings Behavior & Post-Earnings Drift

Clorox has an earnings-beat track record, with 6 beats over the last 8 reported quarters (75% beat rate) and an average earnings surprise of 9.6%. The average 5-day post-earnings price move across those quarters has been +1.67%, classified as an upward drift. Over the trailing four quarters, however, the market’s reaction has been inconsistent.

On August 3, 2026, Clorox reported EPS of $1.66 versus a consensus estimate of $1.64, a 1.2% beat, and the stock rallied 6.52% the next day and 9.61% over the following five days. On April 30, 2026, the company earned $1.64 versus an estimate of $1.55, a 5.8% beat, yet the stock fell 9.67% the next session and was down 4.49% after five days. That divergence shows that a beat alone is not enough when guidance or underlying trends disappoint.

On February 3, 2026, Clorox missed with EPS of $1.39 versus an estimate of $1.43 (-2.8% surprise), but the stock still climbed 2.43% the next day and 5.63% over five days. The November 3, 2025 report delivered $0.85 against $0.818 expected (3.9% beat), with the stock up 1.17% the next day but down 4.08% after five days. With the next report scheduled for November 3, 2026 after the close and the consensus EPS estimate at $1.09, the historical pattern suggests investors should look beyond the headline beat or miss and focus on management commentary around margins, GOJO integration, and ERP execution.

For a deeper dive, readers can examine the full institutional verdict on CLX to weigh how sell-side analysts are modeling the GOJO integration, ERP rollout, and the next earnings report.